
Perioperative nivolumab may bolster survival over only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC
New data from landmark analysis presented today reports a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and ...
Sep 8, 2024
0
0